As pain in the intensive care unit (ICU) is still common despite important progress in pain management, we studied the efficacy of an intravenous bolus of morphine 2.5 vs 7.5 mg for procedural pain relief in patients after cardiothoracic surgery in the ICU. In a prospective double-blind randomised study, 117 ICU patients after cardiothoracic surgery were included. All patients were treated according a pain titration protocol for pain at rest, consisting of continuous morphine infusions and paracetamol, applied during the entire ICU stay. On the first postoperative day, patients were randomised to intravenous morphine 2.5 (n=59) or 7.5 mg (n=58) 30 minutes before a painful intervention (turning of patient and/or chest drain removal). Pain scores using the numeric rating scale (Numeric Rating Scale, range 0 to 10) were rated at rest (baseline) and around the painful procedure. At rest (baseline), overall incidence of unacceptable pain (Numeric Rating Scale ≥4) was low (Numeric Rating Scale >4; 14 vs 17%, P=0.81) for patients allocated to morphine 2.5 and 7.5 mg respectively. For procedure-related pain, there was no difference in incidence of unacceptable pain (28 vs 22%, P=0.53) mean pain scores (2.6 [95% confidence interval 2.0 to 3.2] vs 2.7 [95% confidence interval 2.0 to 3.4]) between patients receiving morphine 2.5 and 7.5 mg respectively. In intensive care patients after cardiothoracic surgery with low pain levels for pain at rest, there was no difference in efficacy between intravenous morphine 2.5 mg or morphine 7.5 mg for pain relief during a painful intervention.
Despite important clinical progress in pain management 1 , patients after cardiothoracic surgery in the intensive care unit (ICU) may suffer from postoperative pain 2, 3 . Procedure-related pain is the most common form of healthcare-induced pain 4 , of which turning of the patient and drain removal have been identified as the most painful procedures 5, 6 . More specifically, patients recall repeated painful procedures as strong negative memories of the time in ICU 7 . Additionally, it has been demonstrated that postoperative pain is a predictor for the development of chronic thoracic pain 8 . When receiving adequate pain relief, ICU patients are reported to be more comfortable, improving patients' outcome such as mortality or morbidity 9 .
For pain at rest, recent studies 2,10,11 showed that a pain training program, in which pain scores were systematically recorded by trained personnel, results in a successful reduction in the occurrence of unacceptable pain at rest. In the study conducted in our ICU 11 , 46% of the patients treated after the introduction of the pain training program experienced at least one unacceptable pain event at rest during their stay. In order to reduce this incidence, a pain titration protocol for pain management at rest is implemented in our ICU, because individualised titration of analgesia is associated with shorter ICU and hospital length of stay and lower mortality 12 .
Apart from pain at rest, ICU patients may suffer during routine healthcare painful procedures. However, according to available evidence, procedural pain is difficult to treat, and some patients will experience unacceptable pain despite treatment [13] [14] [15] . No studies are available in which a bolus of analgesic is used for procedural pain relief in ICU patients already treated with individualised titration of analgesia for pain at rest. Therefore, we designed a randomised controlled study to compare the efficacy of a bolus of intravenous morphine 2.5 vs 7.5 mg for procedural pain relief in postoperative patients after cardiothoracic surgery in the ICU, who were already treated according to a pain titration protocol for pain at rest.
MATERIAlS AND METHODS Design
A prospective, double-blind, randomised clinical trial was performed in a 30-bed surgical/medical ICU in a teaching hospital in Nieuwegein, The Netherlands. The study was approved by the local Ethics Committee of the St Antonius Hospital in Nieuwegein, The Netherlands. Written informed consent was obtained from the patients before the cardiothoracic surgical procedure. The study was registered at ClinicalTrials.gov (identifier NCT00558090).
Patients
During a 10-month period, patients admitted to the ICU after cardiothoracic surgery through sternotomy, aged between 18 and 85 years old and weighing between 45 and 140 kg were included. Exclusion criteria were planned postoperative admission to the postoperative anaesthesia care unit instead of ICU (depending on their comorbidities), pregnancy or breast-feeding, a language barrier, coma or brain death, patients with a known morphine or paracetamol allergy and patients who refused informed consent. Participant flow is summarised in the CONSORT diagram ( Figure 1 ). Of 528 patients who were scheduled for cardiothoracic surgery and assessed for eligibility, 393 were excluded and 135 patients were enrolled in the study. The 42 patients who were excluded because they were not present on the ward during inclusion rounds due to medical examination, did not differ from included study patients in terms of demographic characteristics (age 68±15 vs 69±11 years, P=0.51), (body mass index 26±3 vs 27±4 kg/m 2 , P=0. 14) , mean baseline pain scores (Numeric Rating Scale [NRS] 1.4±1.5 vs 1.5±1.7, P=0.93) or incidence of unacceptable pain scores at baseline (NRS ≥4; 10 vs 13%, P=0.78).
Of the 135 patients enrolled in the study, 16 patients were excluded before randomisation of the study medication ( Figure 1 ). Random allocation resulted in 61 patients assigned to 2.5 mg morphine and 58 patients assigned to the 7.5 mg morphine group. In the patients receiving 2.5 mg morphine, one patient was excluded from analysis because the pain score during the painful procedure was not recorded. One patient was excluded because the intervention was not executed according to the study protocol.
Intraoperative anaesthetic technique during cardiothoracic surgery
In all patients, midazolam or diazepam, fentanyl and propofol were used for induction of anaesthesia. All patients were paralysed with pancuronium. Anaesthesia was maintained with propofol, sevoflurane, nitrous oxide and either fentanyl or remifentanil as preferred by the attending anaesthesiologist.
Pain measurement instruments
The NRS was scored by the patient, which is considered the gold standard for pain measurement 16 . The NRS was explained to participating patients before cardiothoracic surgery. The NRS is based on a scale from 0 to 10, 0 representing no pain and 10 represents worst possible pain 17, 18 . The NRS has a maximal acceptable pain score of 3 19 . Severe pain was defined as a NRS ≥7 20 . The minimum clinically significant difference in pain reduction has been determined to be 1.3 to 1.5 21 , 22 . Where the patient was not able to report his or her pain, the NRS was scored by the nurse, which has been proven to be a reliable measure 23 . There was no difference between mean NRS scores by the patient and mean NRS scored by the nurse before administration of the study dose morphine ( 
Standard pain titration protocol for treatment of pain at rest
For basic pain relief, a standard pain titration protocol ( Figure 2 ) consisting of intravenous morphine infusion and intermittent paracetamol, was used in all patients, and has been current practice in this ICU since 2007. When patients had an NRS score of ≥4, the attending nurse together with the responsible physician administered additional analgesic medication.
Study procedures
According to standard pain titration protocol for pain at rest, patients were treated with continuous morphine infusions. The painful intervention took place during routine healthcare procedures on the first postoperative day after cardiothoracic surgery (day 1), between 0730 and 0930 hours. Patients received either morphine 2.5 or 7.5 mg intravenously, 30 minutes prior to an unavoidable painful routine intervention, i.e. turning of the patient and/or chest drain removal, which were both described as painful by patients 5, 24 . Pain levels using the NRS were assessed at rest (baseline, before administration of a bolus morphine 2.5 or 7.5 mg), five minutes before, during and five minutes after the painful intervention. If necessary, rescue medication (fentanyl) could be administered.
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Sample size calculation
With an incidence of unacceptable pain (NRS ≥4) of 60% 13 during a painful intervention, the sample size needed for a 25% reduction in incidence of unacceptable pain is 120 patients. The sample size was calculated with a power of 0.80 and an alpha of 0.05, two-sided. Turning of the patient and drain removal have been identified as the most painful routine procedures performed for adults 5, 6 , with comparable pain intensity between drain removal and turning of the patient (NRS 6.5±3.9 vs NRS 4.1±3.4) 6 . In our study, there was no difference in pain intensity between turning of the patient and drain removal (NRS 2.2±2.0 vs 3.1±2.7 respectively; P=0.07).
Study medication
Morphine 2.5 and 7.5 mg syringes were prepared using morphine HCl 10 mg in 1 ml solution for injection (Pharmachemie, Haarlem, The Netherlands), which was diluted with sodium chloride 0.9% for a final concentration of morphine 2.5 mg in 10 ml and morphine 7.5 mg in 10 ml respectively. The preparation, packaging and labelling was performed by the Department of Clinical Pharmacy. Syringes were blinded for patients, nurses, physicians and researchers.
Randomisation to morphine 2.5 or 7.5 mg before the painful intervention
Randomisation to one of the two groups was performed using a random allocation schedule generated in blocks of 6 using SPSS. Randomisation was performed in blocks of six patients to ensure that the morphine 2.5 mg group and 7.5 mg group would be of approximately equal size through the course of the study. The studied dose of 7.5 mg was chosen because it corresponds -in combination with the baseline morphine dosage according to the pain titration protocol -to the morphine dosage of 0.15 mg/kg, which was shown to be effective for pain relief in patients with severe pain 20 . The studied dose of 2.5 mg results from our hypothesis that a pain titration pain protocol combined with a low dose or placebo is sufficient to prevent or treat procedural pain.
Endpoints
The primary endpoint of the study was the percentage of patients with an unacceptable pain score (NRS ≥4) at baseline and during painful intervention, in both the group receiving morphine 2.5 mg or 7.5 mg. Secondary endpoints were mean NRS scores during intervention, extreme pain (NRS ≥7) during painful intervention, and clinically relevant decrease or increase in the NRS during the intervention compared with the NRS before intervention.
Data analysis
The SPSS statistical package (version 15.0.1 for Windows; SPSS, Chicago, IL, USA) was used for the statistical analyses. Analysis was conducted in patients allocated to receive morphine 2.5 mg and 7.5 mg, although at baseline (at rest), patients still had to receive the study medication. Descriptive statistics are reported as means with SDs, medians with ranges, and proportions. Means were compared using a t-test for normally distributed data or the nonparametric Mann-Whitney two-sample rank sum test for data not fitting the assumptions of parametric testing. Proportions were compared by using chi-square tests or Fisher's exact test when appropriate. A P value of less than 0.05 was considered statistically significant.
RESUlTS

Baseline patient characteristics
Baseline demographic and clinical characteristics of patients are described in Table 1 . Patients allocated to 7.5 mg morphine were significantly older (72±9 vs 66±12 years, P <0.002), had a higher median EURO score (8 [range 0 to 13] vs 6 [range 2 to 12], P=0.03), and were less often exposed to the combination of turning and drain removal (22 vs 36 patients, P=0.03).
NRS scores at baseline (before administration of a bolus morphine 2.5 or 7.5 mg)
At rest (baseline), the overall incidence of unacceptable pain (NRS ≥4) was low (16%), and comparable between patients planned for randomisation to morphine 2.5 and 7.5 mg (15 vs 17%, P=0.81) (Table 2, Figure 3 ). Mean baseline NRS scores at rest were not different between patients receiving 2.5 and 7.5 mg morphine (1.5 [95% CI 1.2 to 2.0] vs 1.7 [1.1 to 2.2], P=0.62). Patients planned for randomisation to morphine 7.5 mg had significantly less baseline consumption of morphine (13.1±5.9 vs 15.9±5.5 mg, P=0.03) compared to the patients planned for randomisation to morphine 2.5 mg.
Pain scores before, during and after the painful intervention in patients randomised to receive morphine 2.5 vs 7.5 mg
During the intervention, the overall incidence of unacceptable pain (NRS ≥4) was low (25%), 
mg morphine 7.5 mg morphine
and comparable between patients allocated to morphine 2.5 and 7.5 mg (28% and 22% respectively) ( Table 3 , Figure 3 ). In both groups, mean NRS scores were low (2.6 [95% CI 2.0 to 3.2] vs 2.7 [95% CI 2.0 to 3.4]): 8 and 14% of the patients experienced severe pain (NRS ≥7) during the intervention in the morphine 2.5 and 7.5 mg group, respectively. There were no significant differences in mean NRS scores five minutes before, during and five minutes after the painful intervention between patients receiving morphine 2.5 mg and patients receiving morphine 7.5 mg (Table 3 , Figure 3) . No difference was found between the groups in clinically relevant (ΔNRS ≥1.3) decrease (0 vs 3%, P=0.24) or increase (42 vs 38%, P=0.71) in NRS scores. There was also no difference in mean change in NRS scores between both groups (1.5 [95% CI 1.1 to 1.9] vs 1.4 [95% CI 0.1 to 2.6] respectively, P=0.64) (Table 4 ). Additionally, in patients with unacceptable pain at rest (baseline), the mean change in NRS score was similar between patients allocated to morphine 2.5 and 7.5 mg (-1.1 [-2.9 to 0.7] vs 0.4 [-2.1 to 2.9], P=0.27).
None of the patients received fentanyl rescue medication.
DISCUSSION
In this study, we evaluated the efficacy of morphine 2.5 versus 7.5 mg for the prevention and treatment of a non-avoidable painful intervention in ICU patients after cardiothoracic surgery, who were already treated according to a pain titration protocol for pain at rest. In patients with low pain levels for pain at rest, there was no difference in efficacy between a bolus of intravenous morphine 2.5 or 7.5 mg for pain relief during a painful intervention.
During the painful intervention, we found a substantially lower incidence of unacceptable NRS scores (25%), compared to previous reports. In these studies, incidences of 32 to 62% were reported during endotracheal suctioning and movement in patients with various morbidities [13] [14] [15] . In addition, mean NRS scores during the painful intervention were low (Table 3) compared to other studies, in which mean NRS scores of 5 and 7 were recorded during turning and drain removal respectively 5, 6 . In these studies, pain was managed with standard doses of analgesics for pain relief at rest or during procedural interventions only [25] [26] [27] , in contrast to our study using a pain titration protocol. As such, the pain titration protocol which is applied during the entire ICU stay may not affect pain scores at rest alone, but may also lead to a decrease of pain intensity during painful procedures. This is partly explained by the study of Aubrun et al 20 , who concluded that patients with an initial visual analogue scale (VAS) ≥6 more often need rescue medication after morphine titration compared to patients with vAS <6 in the treatment of postoperative pain.
The dose of morphine 7.5 mg in our study was in accordance with the described literature for the prevention of procedural pain. Aubrun et al 20 reported that a threshold of 0.15 mg/kg morphine is needed for pain relief in patients with severe pain (NRS ≥7) during postoperative pain titration. A lower dose of 0.10 mg/kg was less effective compared to 0.15 mg/kg for pain reduction in emergency department patients with acute pain. A higher dose of 0.25 mg/kg morphine was reported to lead to more respiratory depression compared to 0.15 mg/kg 28 . Our dose of morphine 7.5 mg combined with the standard titration protocol is therefore the most optimal dose as it is in accordance with the maximum dose of 0.15 mg/ kg. In contrast, the dose of morphine 2.5 mg results from our hypothesis that a pain titration protocol for managing pain at rest combined with only a low dose of morphine is sufficient to prevent or treat procedural pain. However, we cannot exclude that morphine 2.5 mg is comparable to placebo. In that case, the pain titration protocol is more important for procedural pain management than a bolus of morphine.
Concerning pain at rest, previous reports showed that systematic pain measurement reduced incidences of unacceptable pain (NRS ≥4) at rest to approximately 40% 2,10,11 . In our study, we were able to reduce the incidence of unacceptable pain at rest to 17%, as a result of morphine titration adapted to individual pain. In the group of patients allocated to morphine 7.5 mg, similar NRS scores could be achieved with a lower baseline morphine consumption compared to the patients allocated to morphine 2.5 mg. The difference in morphine consumption can be explained by the difference in baseline characteristics, as patients allocated to morphine 7.5 mg were significantly older and had a higher EURO score. It is well known that older patients need less analgesics for pain relief than younger patients 29 . Patients with a high EURO score are probably more vulnerable to the effects of medication, due to impaired function of elimination organs, e.g. kidney and liver. This may result in a slower elimination of morphine, thereby leading to lower morphine consumption in these patients. Thus, the pain titration protocol leads to an individual dosing regimen of analgesics, thereby resulting a low incidence of unacceptable pain at rest (17%).
Some remarks must be included concerning the limitations of our study. First, patients receiving 7.5 mg were more often exposed to the intervention 'drain removal', which may be more painful than the intervention 'turning' and thus may have reduced the difference in effect of pain relief between the patients receiving 2.5 mg and 7.5 mg. However, there was no significant difference in pain intensity between turning and drain removal. Second, the low procedural pain levels may theoretically have contributed to the reported lack of difference in pain levels between the morphine 2.5 and 7.5 mg group. That is, as a result of the low overall pain scores which the patients reported within the context of the pain titration protocol, further decrease in pain intensity is more difficult to detect. In the ideal study design, we would have compared morphine 7.5 mg with placebo in combination with the pain titration protocol. However, for ethical considerations we preferred to treat these patients with a low dose of morphine. In this context, morphine may be dosed on kg body weight instead of a fixed dose. Finally, it cannot be excluded that the low overall pain scores were a consequence of the clinical trial itself. During a clinical trial with relation to pain management, all health workers in the ICU will be 'affected' in their approach to pain treatment.
In conclusion, in intensive care patients after cardiothoracic surgery with low pain levels for pain at rest, there was no difference in efficacy between a bolus of intravenous morphine 2.5 mg or morphine 7.5 mg for pain relief during a painful intervention.
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